Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company specializing in allergic and immunologic diseases, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for September 5th in New York City.
This conference provides Astria Therapeutics with a platform to showcase its progress in developing life-changing therapies and potentially connect with investors and industry professionals. The company's attendance at such a prestigious healthcare conference highlights its commitment to advancing its research and development efforts in the field of allergic and immunologic diseases.
Astria Therapeutics (Nasdaq: ATXS), un'azienda biofarmaceutica specializzata in malattie allergiche e immunologiche, ha annunciato la sua partecipazione al 22° Annual Global Healthcare Conference di Morgan Stanley. L'evento è programmato per il 5 settembre a New York City.
Questa conferenza offre ad Astria Therapeutics una piattaforma per mostrare i suoi progressi nello sviluppo di terapie che cambiano la vita e potrebbe consentirle di connettersi con investitori e professionisti del settore. La partecipazione dell'azienda a una conferenza sanitaria così prestigiosa sottolinea il suo impegno a far progredire le proprie attività di ricerca e sviluppo nel campo delle malattie allergiche e immunologiche.
Astria Therapeutics (Nasdaq: ATXS), una empresa biofarmacéutica especializada en enfermedades alérgicas e inmunológicas, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. El evento está programado para el 5 de septiembre en Ciudad de Nueva York.
Esta conferencia proporciona a Astria Therapeutics una plataforma para mostrar su progreso en el desarrollo de terapias que cambian la vida y potencialmente conectarse con inversores y profesionales de la industria. La asistencia de la empresa a una conferencia de salud tan prestigiosa destaca su compromiso con el avance de sus esfuerzos de investigación y desarrollo en el campo de las enfermedades alérgicas e inmunológicas.
Astria Therapeutics(Nasdaq: ATXS)는 알레르기 및 면역 질환을 전문으로 하는 바이오 제약 회사로, 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 이 행사는 9월 5일에 뉴욕시에서 예정되어 있습니다.
이 컨퍼런스는 Astria Therapeutics가 생명을 변화시키는 치료법 개발의 진행 상황을 보여줄 수 있는 플랫폼을 제공하며, 잠재적으로 투자자 및 업계 전문가와 연결할 기회를 제공합니다. 회사가 이렇게 권위 있는 헬스케어 컨퍼런스에 참석하는 것은 알레르기 및 면역 질환 분야에서 연구 및 개발 노력을 발전시키겠다는 헌신을 강조합니다.
Astria Therapeutics (Nasdaq: ATXS), une entreprise biopharmaceutique spécialisée dans les maladies allergiques et immunologiques, a annoncé sa participation à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. L'événement est prévu pour le 5 septembre à New York City.
Cette conférence offre à Astria Therapeutics une plateforme pour présenter ses avancées dans le développement de thérapies révolutionnaires et permet éventuellement de se connecter avec des investisseurs et des professionnels de l'industrie. La participation de l'entreprise à une conférence de santé aussi prestigieuse souligne son engagement à faire progresser ses efforts de recherche et développement dans le domaine des maladies allergiques et immunologiques.
Astria Therapeutics (Nasdaq: ATXS), ein biopharmazeutisches Unternehmen, das sich auf allergische und immunologische Erkrankungen spezialisiert hat, hat seine Teilnahme an der 22. jährlichen Global Healthcare Conference von Morgan Stanley bekanntgegeben. Die Veranstaltung ist für den 5. September in New York City geplant.
Diese Konferenz bietet Astria Therapeutics eine Plattform, um seine Fortschritte bei der Entwicklung von lebensverändernden Therapien zu präsentieren und möglicherweise mit Investoren und Branchenexperten in Kontakt zu treten. Die Teilnahme des Unternehmens an einer so prestigeträchtigen Gesundheitskonferenz hebt sein Engagement hervor, seine Forschungs- und Entwicklungsanstrengungen im Bereich der allergischen und immunologischen Erkrankungen voranzutreiben.
- None.
- None.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829008062/en/
Astria Contact:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
When and where is Astria Therapeutics (ATXS) participating in the Morgan Stanley Healthcare Conference?
What is the focus of Astria Therapeutics (ATXS) in terms of drug development?
What stock exchange is Astria Therapeutics (ATXS) listed on?
Why is Astria Therapeutics (ATXS) participating in the Morgan Stanley Healthcare Conference?
